Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study

Hematology/Oncology and Stem Cell Therapy

Hosam E. Ahmed¹  Bassim Albeirouti²  Zayed Alzahrani²  Naif I. AlJohani²  Azhar Nawaz²  Jalil Ur Rehman²  Momen Nasani³ 

[1] Adult Hematology and Bone Marrow Transplant Section, Oncology Department, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia;Adult Hematology and Bone Marrow Transplant Section, Oncology Department, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia;Corresponding author at: Adult Hematology and BMT Section, Oncology Department, King Faisal Specialist Hospital and Research Centre, Al Rawdah Street, Jeddah, Saudi Arabia.;

关键词: Autologous stem cell transplant;    BCNU;    Bendamustine;    Carmustine;    Lymphoma;    Toxicity;   

DOI  :  

来源: DOAJ

【 摘 要 】

BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to assess the feasibility of bendamustine as an alternative to BCNU. We compared 71 patients who received either bendamustine (Benda-EAM group) or BCNU (BEAM group) conditioning. Considering previous reports of increased cardiotoxicity, nephrotoxicity, and mucositis, we adopted a lower bendamustine dose of 160 mg/m2/day administered for 2 days. There was no increase in nephrotoxicity and cardiotoxicity. Further, positive results were also obtained for neutrophil and platelet engraftment, appearing earlier in patients treated with Benda-EAM (10 vs. 14 days and 16 vs. 27 days, respectively). However, caution is warranted because an increased frequency of Grade 3 mucositis was observed in the Benda-EAM group (82.4% vs. 48%). This was accompanied by an increased need for parenteral nutrition. Despite the lower dose of bendamustine, the overall and progression-free survival rates were comparable between the Benda-EAM and BEAM groups. In conclusion, a lower dose of bendamustine may be an attractive alternative to BCNU as a tolerable treatment modality for patients with relapsed/refractory lymphoma.

【 授权许可】

Unknown